He instruido el envío de una misión de rescatistas y personal de Sinaproc a Venezuela a fin de colaborar en las misiones de rescate y salvamento Esperamos que se logre pronto estabilizar los efectos de esta tragedia.
Nuestra mayor solidaridad y acompañamiento a Venezuela por el terremoto y sus consecuencias. Panamá, una vez más, ofrece su ayuda humanitaria a países hermanos.
Felicito a @ABDELAESPRIELLA por su victoria en Colombia.
Le deseo el mayor de los éxitos en la responsabilidad que asume al frente de su país. Panamá reitera su disposición de seguir fortaleciendo los lazos de amistad, cooperación y desarrollo entre nuestras naciones.
Mis mejores deseos para el pueblo colombiano.
New study of 111,646 women: GLP-1 use was linked to about 30% lower breast cancer incidence.
For scale, tamoxifen (the drug we prescribe to prevent it) runs about 38%, minus the endometrial cancer and clot risk.
Not proof yet, but looks very promising.
It’s strange that we ask trainees to read clinical trials but never really teach them how to read clinical trials.
I’d request all training program directors and mentors to please share this article to their trainees and fellows- https://t.co/HJhZlsAS4u
Grateful to @JCOOP_ASCO for making this free.
Arrêtez de payer pour Claude IA.
L'IA de Mc Donald's est gratuite et répond à toutes les questions, même si elles ne sont pas sur le BIG MAC.
:-)
De rien.
A massive Nature study of 27,885 GLP-1 users just dropped some major news about Ozempic and tirzepatide.
Your DNA determines how much weight you lose and how bad the side effects hit.
1 in 3 people see minimal results, and now we know why: (1/9)
Doctors take more high-stakes exams than virtually any other profession.
Over 10+ years of this, I became obsessed with one question: which study techniques actually work?
Here's how I learned to study less and score higher
🧵1/11
this is actually insane
> be tech guy in australia
> adopt cancer riddled rescue dog, months to live
> not_going_to_give_you_up.mp4
> pay $3,000 to sequence her tumor DNA
> feed it to ChatGPT and AlphaFold
> zero background in biology
> identify mutated proteins, match them to drug targets
> design a custom mRNA cancer vaccine from scratch
> genomics professor is “gobsmacked” that some puppy lover did this on his own
> need ethics approval to administer it
> red tape takes longer than designing the vaccine
> 3 months, finally approved
> drive 10 hours to get rosie her first injection
> tumor halves
> coat gets glossy again
> dog is alive and happy
> professor: “if we can do this for a dog, why aren’t we rolling this out to humans?”
one man with a chatbot, and $3,000 just outperformed the entire pharmaceutical discovery pipeline.
we are going to cure so many diseases.
I dont think people realize how good things are going to get
Now that everyone is an expert on curing pancreatic cancer in mice, not rats - I want to add some context that goes beyond the headline.
You will want to read this.
Cancer is cured in mice all the time.
Thousands of times. ~90% of those “cures” fail in humans.
Why?
Because mice are:
Genetically simpler.
Treated earlier.
Short-lived.
Not humans.
Mice are a filter - not a finish line.
Yes, this study matters. It comes from the Spanish National Cancer Research Centre.
Yes, it’s pancreatic cancer - one of the deadliest there is. Yes, full tumor regression is impressive.
But here’s what it actually means:
“This approach is now good enough to risk years, trials, and millions of euros on.”
Not:
“Cancer is solved.”
What happens next?
More animal work.
Toxicology.
Phase I (safety).
Phase II (maybe works).
Phase III (beats standard care?).
Maybe 8-10 years if everything goes right.
The real damage isn’t failed drugs.
It’s failed expectations.
Every “cured cancer in mice” headline trains the public to believe:
Cures are being hidden.
Progress should be fast.
Scientists are lying when reality hits.
That’s how trust erodes.
Bottom line:
This is how real cancer progress looks.
Messy. Slow. Risky. Incremental.
Not miracles.
Not conspiracies.
Just science - doing the hard work.